Sonoma Pharmaceuticals Inc (SNOA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $5.52M
Last updated: Nov 17, 2026 at 4:15 PM ET
Sonoma Pharmaceuticals Inc (SNOA) Statistics
Sonoma Pharmaceuticals (SNOA) has a market cap of $5.52M and an enterprise value of $965.10K. Its share count is up 198.24% from a year earlier. It holds $4.55M more cash than debt, 82.51% of its market cap.
Total Valuation
Enterprise value is 82.51% below the market cap, as cash exceeds debt.
| Market Cap | $5.52M |
|---|---|
| Enterprise Value | $965.10K |
| Latest price (Nov 17, 2026) | $0.84 |
Key Dates
The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | March |
Valuation Ratios
Sales and book value multiples are 0.2x and 0.6x. Its year-end P/S ranged from 0.2x to 17.1x from 2019 to 2025.
| P/S Ratio | 0.2x |
|---|---|
| Forward P/S | 0.2x |
| P/B Ratio | 0.6x |
Price Statistics
The stock is down 75.58% over 52 weeks and trades 28.81% below its 50-day average.
| Beta (1Y) | 1.43 |
|---|---|
| 52-Week Change | -75.58% |
| 1-Month Change | -24.99% |
| 3-Month Change | -38.23% |
| 6-Month Change | -16.82% |
| 5-Year Change | -99.05% |
| 10-Year Change | -99.85% |
| Total Return (1Y) | -75.58% |
| Total Return (3Y CAGR) | -35.88% |
| Total Return (5Y CAGR) | -62.17% |
| Max Drawdown (1Y) | -77.89% |
| Max Drawdown (3Y) | -90.16% |
| Sharpe Ratio (1Y) | -1.79 |
| Correlation with SPY (1Y) | 0.24 |
| 50-Day Average | $1.18 |
| 200-Day Average | $1.57 |
| 52-Week Range | $0.80 to $3.95 |
| RSI (14 Days) | 29.2 |
| Average Volume (20 Days) | 87.01K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.48x current liabilities, and total debt is 0.01x shareholder equity.
| Current Ratio | 3.48x |
|---|---|
| Quick Ratio | 2.68x |
| Debt / Equity | 0.01x |
Returns and Efficiency
Return on invested capital is -20.90% over the last 12 months, against a 5-year average of -95.72%.
| Return on Equity (ROE) | -27.15% |
|---|---|
| Return on Assets (ROA) | -10.50% |
| Return on Invested Capital (ROIC) | -20.90% |
| Return on Capital Employed (ROCE) | -10.99% |
| ROE (5Y Average) | -76.56% |
| ROA (5Y Average) | -27.90% |
| ROIC (5Y Average) | -95.72% |
| Asset Turnover | 1.52x |
| Inventory Turnover | 3.91x |
| Receivables Turnover | 6.95x |
| Cash Conversion Cycle | 31 days |
Scores
SNOA has an Altman Z-Score of -14.38, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -14.38 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $23.49M over the last 12 months is up 38.69% from the 12 months before.
| Revenue | $23.49M |
|---|---|
| Revenue Growth (YoY) | +38.69% |
| Gross Profit | $9.21M |
| Operating Income | -$779.00K |
| Pretax Income | -$1.39M |
| Net Income | -$1.80M |
| EBIT | -$1.39M |
| Reported EPS (TTM) | -$0.52 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 38.65% of the $17.10M in total assets.
| Cash and Equivalents | $4.61M |
|---|---|
| Total Debt | $57.00K |
| Net Cash | $4.55M |
| Net Cash Per Share | $0.93 |
| Working Capital | $10.93M |
| Shareholder Equity | $6.61M |
| Book Value Per Share | $1.35 |
| Total Assets | $17.10M |
| Total Liabilities | $10.49M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $120.00K of capital spending, operating cash flow left -$2.79M of free cash flow.
| Operating Cash Flow | -$2.67M |
|---|---|
| Capital Expenditures | $120.00K |
| Free Cash Flow | -$2.79M |
| FCF Per Share | -$0.58 |
| Depreciation and Amortization | $129.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -3.32%, against a 5-year average of -31.31%.
| Gross Margin | 39.23% |
|---|---|
| Operating Margin | -3.32% |
| Pretax Margin | -5.93% |
| Net Margin | -7.65% |
| EBIT Margin | -5.93% |
| FCF Margin | -11.87% |
| Gross Margin (5Y Average) | 35.77% |
| Operating Margin (5Y Average) | -31.31% |
| Net Margin (5Y Average) | -31.50% |
Growth
Revenue grew 13.74% a year over 3 years.
| Revenue Growth (3Y CAGR) | +13.74% |
|---|---|
| Revenue Growth (5Y CAGR) | +0.95% |
| Book Value Per Share Growth (2Y CAGR) | -52.77% |
| Tangible Book Per Share Growth (2Y CAGR) | -52.77% |
Dividends and Yields
SNOA does not pay a dividend. Its free cash flow yield is -67.60%.
| FCF Yield | -67.60% |
|---|---|
| Buyback Yield | -103.66% |
| Shareholder Yield | -103.66% |
Stock Splits
The last split was a 1-for-20 reverse split on Aug 30, 2024.
| Last Split Date | Aug 30, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Peer Position
Against 5 similar companies, SNOA has the lowest P/S.
P/S RatioPeer median 1.6x
ROICPeer median -61.17%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +2.39%
| P/S Ratio | 0.2x vs 1.6x median |
|---|---|
| ROIC | -20.90% vs -61.17% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +38.69% vs +2.39% median |
Analyst Forecast
Consensus estimates put revenue growth at 22.44% a year over the next fiscal year.
| Revenue Growth Forecast (1Y CAGR) | +22.44% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SNOA
What is SNOA's market cap?
Sonoma Pharmaceuticals has a market cap of $5.52M. Its enterprise value, which adds debt and subtracts cash, is $965.10K.
How many shares of SNOA are outstanding?
Sonoma Pharmaceuticals has 4.91M shares outstanding. The count is up 198.24% from a year earlier.
Does SNOA pay a dividend?
No. Sonoma Pharmaceuticals does not pay a dividend.
How much debt does SNOA have?
Sonoma Pharmaceuticals has $57.00K of total debt and $4.61M of cash and equivalents, a net cash position of $4.55M.
SNOA pages: Overview, Charting, Earnings, Financials, Statistics, Valuation, Competitors